217171-01-2

Basic information

• Product Name: N-[[4-(1,1-Dimethylethyl)phenyl]methyl-N-methyl-L-leucyl-N-(1,1-dimethylethyl)-O-phenylmethyl)-L-tyrosinamide
• Synonyms: N-[[4-(1,1-Dimethylethyl)phenyl]methyl-N-methyl-L-leucyl-N-(1,1-dimethylethyl)-O-phenylmethyl)-L-tyrosinamide;PD 173212
• CAS NO: 217171-01-2
• Molecular Formula: C38H53N3O3
• Molecular Weight: 599.84572
• Mol File: 217171-01-2.mol

Chemical Properties

• Boiling Point: 753.4±60.0 °C(Predicted)
• Appearance: /
• Density: 1.053±0.06 g/cm3(Predicted)
• Storage Temp.: Store at +4°C
• PKA: 13.83±0.46(Predicted)
• CAS DataBase Reference: N-[[4-(1,1-Dimethylethyl)phenyl]methyl-N-methyl-L-leucyl-N-(1,1-dimethylethyl)-O-phenylmethyl)-L-tyrosinamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[[4-(1,1-Dimethylethyl)phenyl]methyl-N-methyl-L-leucyl-N-(1,1-dimethylethyl)-O-phenylmethyl)-L-tyrosinamide(217171-01-2)
• EPA Substance Registry System: N-[[4-(1,1-Dimethylethyl)phenyl]methyl-N-methyl-L-leucyl-N-(1,1-dimethylethyl)-O-phenylmethyl)-L-tyrosinamide(217171-01-2)

Safety Data

• Hazardous Substances Data: 217171-01-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PD 173212 is used as a research compound for studying the role of N-type calcium channels in various neurological disorders. Its ability to block these channels makes it a valuable tool in understanding the underlying mechanisms of conditions such as epilepsy, chronic pain, and certain types of cancer.
Used in Preclinical Research:
PD 173212 is used as a preclinical agent to evaluate its potential therapeutic effects in animal models of audiogenic seizures. When administered at a dose of 30 mg/kg, it has been shown to prevent audiogenic seizures in mice, indicating its potential as a treatment option for seizure disorders.
Used in Drug Development:
PD 173212 serves as a lead compound in the development of new drugs targeting N-type calcium channels. Its selective inhibition of these channels can be exploited to create novel therapeutics for a range of conditions, including neurological disorders, pain management, and cancer treatment.

Upstream product

• 939-97-9 4-tert-Butylbenzaldehyde 
• 217171-22-7 (S)-4-Methyl-2-methylamino-pentanoic acid [(S)-2-(4-benzyloxy-phenyl)-1-tert-butylcarbamoyl-ethyl]-amide 
• 217172-81-1 4-methyl-2-methylamino-pentanoic acid [2-(4-benzyloxy-phenyl)-1-tert-butylcarbamoyl-ethyl]-amide 
• 18880-00-7 1-(bromomethyl)-4-(1,1-dimethylethyl)benzene 
• 217172-32-2 {1-[2-(4-benzyloxy-phenyl)-1-tert-butylcarbamoyl-ethylcarbamoyl]-3-methyl-butyl}-methyl-carbamic acid tert-butyl ester 
• 217172-23-1 (S)-2-amino-3-(4-benzyloxy-phenyl)-N-tert-butyl-propionamide 
• 53363-89-6 N-t-butoxycarbonyl-N-methyl-L-leucine 
• 2130-96-3 O-benzyl-N-tert-butoxycarbonyl-L-tyrosine 
• 217172-22-0 (S)-[2-(4-benzyloxy-phenyl)-1-tert-butylcarbamoyl-ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Substituted peptidylamine calcium channel blockers

PCT No. PCT/US98/10838 Sec. 371 Date Jan. 19, 1999 Sec. 102(e) Date Jan. 19, 1999 PCT Filed May 28, 1998 PCT Pub. No. WO98/54123 PCT Pub. Date Dec. 3, 1998The present invention provides compounds that block calcium channels having the Formula I shown belo

Structure-activity relationship of N-methyl-N-aralkylpeptidylamines as novel N-type calcium channel blockers

Selective N-type voltage sensitive calcium channel (VSCC) blockers have shown efficacy in several animal models of stroke and pain. In the process of searching for small molecule N-type calcium channel blockers, we have identified a series of N-methyl-N-aralkyl-peptidylamines with potent functional activity at N-type VSCCs. The most active compound discovered in this series is PD 173212 (11, IC50 = 36 nM in the IMR32 assays). SAR and pharmacological evaluation of this series are described.